FLSM
ETNB

Frazier Life Sciences Management’s 89bio ETNB Stock Holding History

Frazier Life Sciences Management’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000,000
Closed -$7.82M – 52
2024
Q4 		$7.82M Hold
1,000,000
– – 0.32% 41
2024
Q3 		$7.4M Hold
1,000,000
– – 0.3% 44
2024
Q2 		$8.01M Hold
1,000,000
– – 0.37% 37
2024
Q1 		$11.6M Sell
1,000,000
-1,000,000
-50% -$11.1M 0.49% 41
2023
Q4 		$22.3M Buy
+2,000,000
New +$18.4M 1.19% 24

Other funds holding ETNB

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Frazier Life Sciences Management's ETNB Position: Q1 2025 in Review

Frazier Life Sciences Management sold out of 89bio (ETNB) in Q1 2025, closing a stake of 1,000,000 shares — an estimated $7.82M sold.

Frazier Life Sciences Management first reported a position in ETNB in Q4 2023 and held it in 5 quarters. The position peaked at $22.3M in Q4 2023. 186 funds tracked by Wall St. Rank hold ETNB as of Q1 2025.

  • Frazier Life Sciences Management reported no remaining 89bio position as of Q1 2025 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,000,000 89bio shares in Q1 2025, an estimated $7.82M.
  • Frazier Life Sciences Management first reported a position in 89bio in Q4 2023 and held it in 5 quarters.
  • Frazier Life Sciences Management's 89bio position peaked at $22.3M in Q4 2023.
  • 186 funds tracked by Wall St. Rank held 89bio as of Q1 2025.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.